Figure 4.
Changes in beta-cross laps values from the beginning of the study (time point 0) until the end of study (time point 5) for Placebo and PMA-treated patients. A separate representation for the patients enrolled as Placebo group at time point 0 (later treated with PMA-zeolite from time point 1–5) and enrolled patients treated with PMA-zeolite from the beginning of the study (time point 0–5) is given in the Supplementary Figure 1.